Advanced Progress of Histone Deacetylases in Rheumatic Diseases
Xue-Mei Liu,Liu Yang,Qi-Bin Yang
DOI: https://doi.org/10.2147/jir.s447811
IF: 4.5
2024-02-13
Journal of Inflammation Research
Abstract:Xue-Mei Liu, 1, 2, &ast Liu Yang, 1, 2, &ast Qi-Bin Yang 1 1 Department of Rheumatology and Immunology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, 637000, People's Republic of China; 2 Department of Clinical Medicine, Graduate School of North Sichuan Medical College, Nanchong, Sichuan Province, 637000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Qi-Bin Yang, Department of Rheumatology and Immunology, Affiliated Hospital, North Sichuan Medical College, 1 Maoyuannan Road, Nanchong, Sichuan Province, 637000, People's Republic of China, Tel +86-817-259-8221, Email Rheumatic disease is a disease which is not yet fully clarified to etiology and also involved in a local pathological injury or systemic disease. With the continuous improvement of clinical medical research in recent years, the development process of rheumatic diseases has been gradually elucidated; with the intensely study of epigenetics, it is realized that environmental changes can affect genetics, among which histone acetylation is one of the essential mechanisms in epigenetics. Histone deacetylases (HDACs) play an important role in regulating gene expression in various biological processes, including differentiation, development, stress response, and injury. HDACs are involved in a variety of physiological processes and are promising drug targets in various pathological conditions, such as cancer, cardiac and neurodegenerative diseases, inflammation, metabolic and immune disorders, and viral and parasitic infections. In this paper, we reviewed the roles of HDACs in rheumatic diseases in terms of their classification and function. Keywords: histone deacetylase, histone deacetylase inhibitor, rheumatic diseases Epigenetic regulation plays a vital role in gene regulation through chemical modifications of DNA and post-translational modifications of histones. Many studies in recent years have found epigenetic involvement in the pathogenesis of rheumatic immune diseases, and histone acetylation is one of the crucial mechanisms in epigenetics. 1 So far, the family of mammalian zinc-dependent histone deacetylases (HDACs) can be divided into three classes: 2 Class I (HDACs 1–3, 8), Class II (IIa: HDACs 4, 5, 7, 9; IIb: HDACs 6, 10) and Class IV (HDAC 11); and Class III, a family of sirtuin proteins, including SIRT 1–7, where the deacetylation of histones and non-histones by HDACs alters the chromatin conformation and changes the activity of transcription factors, leading to changes in gene expression. 1,3,4 HDACs have different expression sites, distribution and regulation of target genes, Immune diseases are closely related to acetylation levels, and histone deacetylase inhibitors could prevent the onset and progression of disease and be a new approach to treating rheumatic disorders. This review focused on the progress of HDACs research about immune regulation involved in rheumatic diseases to provide a basis for clinical treatment (Table 1). Table 1 Effects of HDACs in Rheumatic Diseases Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic synovitis with severe pain and swelling, joint damage and disability, ultimately leading to destruction and loss of function. 39 The current worldwide prevalence of RA is 0.5%. 40 Recently, it was suggested that epigenetic factors linking genetics and gene expression to disease risk could be a promising area. 41 Histone deacetylase 1 (HDAC1) is closely associated with the development of RA. HDAC1 interferes with the differentiation, maturation, and apoptosis of osteoclasts and promotes the development of bone destruction in RA. 42 Hawtree et al found that HDAC1 expression was significantly higher in RA synovial fibroblasts (RASFs) than in osteoarthritic (OA) synovial fibroblasts (OASFs). It was demonstrated in vitro experiments that HDAC1 knockdown inhibited the proliferation, migration, and invasion of RASFs, and inhibition of HDAC1 significantly reduced joint swelling and attenuated cartilage and joint damage in RA animal models. 5 Moreover, many T cells could be detected in the synovium of RA patients. T cells were viewed to play a central role in the pathogenesis of RA due to their ability to drive the activation of B cells, monocytes, macrophages, and fibroblast-like synoviocytes. 6 Göschl et al found a significant reduction in inflammatory cytokines interleukin (IL)-17 and IL-6 in the serum from mice with T cell-specific deletion of HDAC1, demonstrating that mice with T cell-specific deletion of HDAC1 were resistant to the development of collagen-induced arthritis (CIA). 43 -Abstract Truncated-
immunology